Brief: Abionyx Pharma: New Positive Results In Ophthalmology For First Class Of CER-001-Based Biomedicines

Abionyx Pharma SA

21/11/2023 06:09

Nov 21 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ANNOUNCES NEW POSITIVE RESULTS IN A UVEITIS MODEL FOR THE
STRATEGIC DEVELOPMENT OF THE FIRST CLASS OF BIOMEDICINES IN
OPHTHALMOLOGY BASED ON ITS RECOMBINANT APOA-I
    * SIGNIFICANT EFFICACY OF CER-001 AFTER A SINGLE INTRAOCULAR
ADMINISTRATION IN A UVEITIS MODEL WITH SEVERE INFLAMMATION
COMPARED WITH STANDARD AND BEST-IN-CLASS DRUGS
    * APPOINTMENT OF MR JÉRÔME MARTINEZ AS SENIOR ADVISOR FOR
OPHTHALMOLOGY 

Source text for Eikon:  ID:nBw6YyRWa 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))